dengvaxia
sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - la dengue - vaccins - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 et 4. l'utilisation de dengvaxia doit être en conformité avec les recommandations officielles.
circomax myco
zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologiques pour les suidés - les porcs (pour l'engraissement) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection. onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination. duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination. in addition, vaccination has been shown to reduce body weight gain losses under field conditions.
suvaxyn circo+mh rtu
zoetis belgium sa - inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 orf2 protein, inactivated mycoplasma hyopneumoniae, strain p-5722-3 - viraux inactivés et les vaccins bactériens inactivés - les cochons - pour active la vaccination des porcs à partir de 3 semaines d'âge contre le circovirus porcin de type 2 (pcv2) afin de réduire la charge virale dans le sang et les tissus lymphoïdes et les matières fécales causée par une infection par le pcv2. pour l'immunisation active des porcs âgés de plus de 3 semaines contre mycoplasma hyopneumoniae afin de réduire les lésions pulmonaires causées par une infection à m. hyopneumoniae.
tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymphome, cellule du manteau - agents antinéoplasiques - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).
simulect poudre pour solution
novartis pharmaceuticals canada inc - basiliximab - poudre pour solution - 20mg - basiliximab 20mg - immunosuppressive agents
abecma suspension
celgene inc - idécabtagène vicleucel - suspension - 520000000cellules - idécabtagène vicleucel 520000000cellules - gene therapy
remsima poudre pour solution
celltrion healthcare co ltd - infliximab - poudre pour solution - 100mg - infliximab 100mg - disease-modifying antirheumatic agents
rituxan sc solution
hoffmann-la roche limited - rituximab - solution - 1600mg - rituximab 1600mg - antineoplastic agents
reopro solution
janssen inc - abciximab - solution - 2mg - abciximab 2mg - miscellaneous therapeutic agents
inflectra poudre pour solution
celltrion healthcare co ltd - infliximab - poudre pour solution - 100mg - infliximab 100mg - disease-modifying antirheumatic agents